A Prospective, Single-Blind, Randomized Study to Evaluate Intravitreal Aflibercept Injection (IAI) Versus Sham as PROphylaxis Against CONversion to Neovascular Age-Related Macular Degeneration (AMD) in High-Risk Eyes

Trial Profile

A Prospective, Single-Blind, Randomized Study to Evaluate Intravitreal Aflibercept Injection (IAI) Versus Sham as PROphylaxis Against CONversion to Neovascular Age-Related Macular Degeneration (AMD) in High-Risk Eyes

Recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Apr 2016

At a glance

  • Drugs Aflibercept (Primary)
  • Indications Age-related macular degeneration
  • Focus Therapeutic Use
  • Acronyms PRO-CON
  • Most Recent Events

    • 30 Mar 2016 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
    • 09 Jun 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top